Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stereotactic injection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Stereotactic injection. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-003994-80 Sponsor Protocol Number: ET18-270 Start Date*: 2019-10-03
    Sponsor Name:Centre Léon Bérard
    Full Title: A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases
    Medical condition: Brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001209-26 Sponsor Protocol Number: ICO-N-2018-14 Start Date*: 2019-06-11
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Multicentre, randomized, controlled, open-label, multi-centre medico-economic study evaluating the efficacy of adding zoledronic acid to Stereotaxic radiotherapy in the treatment of vertebral metas...
    Medical condition: Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027484 Metastatic pain LLT
    20.0 100000004864 10027474 Metastatic LLT
    20.0 100000004864 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002417-21 Sponsor Protocol Number: AK2016-2 Start Date*: 2016-09-22
    Sponsor Name:Rigshospitalet
    Full Title: uPAR-PET/MR in glioma
    Medical condition: Gliomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000679-28 Sponsor Protocol Number: FAZA-gliomi Start Date*: 2015-07-13
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Prognostic value of 18F-FAZA PET/CT in high grade glioma: comparison with MRI and correlation with hypoxia biomarkers.
    Medical condition: Patients with high-grade glioma (III-IV).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10018339 Gliomas benign HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002599-35 Sponsor Protocol Number: 2022-1-58-002 Start Date*: 2022-10-21
    Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis
    Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study.
    Medical condition: glioma (grade OMS II à IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001577-33 Sponsor Protocol Number: D24-DIPG Start Date*: 2016-11-03
    Sponsor Name:Clínica Universidad de Navarra
    Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.
    Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001614-16 Sponsor Protocol Number: 16TETE04 Start Date*: 2016-09-22
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma.
    Medical condition: Recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003513-14 Sponsor Protocol Number: DC1 Start Date*: 2009-05-20
    Sponsor Name:Department of Neurology, Karolinska University Hospital [...]
    1. Department of Neurology, Karolinska University Hospital
    2. Dept. of Pediatric hematology and oncology, Astrid Lindgren Children´s Hosp,Karolinska Univ Hospital
    Full Title: Imune therapy of High Grade Glioma with dendritic cell vaccination. A phase II study.
    Medical condition: High grade glioma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003124-12 Sponsor Protocol Number: B-40320109424 Start Date*: 2012-10-30
    Sponsor Name:Cliniques Universitaires Saint Luc
    Full Title: A prospective phase II study on dose escalation using PET based adaptive IMRT stage II-III non small lung cancer
    Medical condition: Stage II-III Non small lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003011-22 Sponsor Protocol Number: ETOP_14-18 Start Date*: 2019-10-10
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the prima...
    Medical condition: Synchronous oligo-metastatic Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003827-31 Sponsor Protocol Number: ICO-N-2017-08 Start Date*: 2018-07-16
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial
    Medical condition: oligometastatic hormone sensitive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007463 Carcinoma prostatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000868-15 Sponsor Protocol Number: P001151 Start Date*: 2019-01-15
    Sponsor Name:Medical Center -University of Freiburg
    Full Title: Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial.
    Medical condition: Aneurysmal Subarachnoid Hemorrhage (aSAH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001378-13 Sponsor Protocol Number: 001 Start Date*: 2017-02-02
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.
    Medical condition: cervical dystonia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10064124 Cervical dystonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002453-38 Sponsor Protocol Number: 15-102-14 Start Date*: 2017-01-17
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been...
    Medical condition: Metastatic breast cancer with stable brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) CZ (Completed) BE (Completed) PT (Completed) FR (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005647-24 Sponsor Protocol Number: MIA2019/CT/258 Start Date*: 2021-05-10
    Sponsor Name:Melanoma Institute Australia
    Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met...
    Medical condition: melanoma brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001109-26 Sponsor Protocol Number: PS1/001/07 Start Date*: 2010-11-04
    Sponsor Name:Oxford BioMedica (UK) Ltd
    Full Title: A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease
    Medical condition: Patients with bilateral, idiopathic Parkinson's Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003127-41 Sponsor Protocol Number: BT009E Start Date*: 2021-05-12
    Sponsor Name:INSIGHTEC
    Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla...
    Medical condition: Recurrent Glioblastoma (rGBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002058-11 Sponsor Protocol Number: CRO-2015-17 Start Date*: 2016-01-05
    Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO
    Full Title: RIMMEL STUDY: Radiotherapy and ipilimumab in melanoma. Phase II clinical trial in patients with metastatic melanoma
    Medical condition: metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003025-37 Sponsor Protocol Number: 2020AFA01 Start Date*: 2020-10-06
    Sponsor Name:VU University Medical Center
    Full Title: COMBINING AFATINIB AND CONCURRENT CHEMOTHERAPY, FOLLOWED BY OSIMERTINIB AND CONCURRENT CHEMOTHERAPY, IN UNTREATED EGFR POSITIVE NSCLC TUMORS
    Medical condition: non small cell lung cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000670-22 Sponsor Protocol Number: 301 Start Date*: Information not available in EudraCT
    Sponsor Name:Y-mAbs Therapeutics, Inc.
    Full Title: A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory M...
    Medical condition: Medulloblastoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 00:40:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA